Type 1 phosphatase, a negative regulator of cardiac function

Andrew N. Carr, Albrecht G. Schmidt, Yoichi Suzuki, Federica Del Monte, Yoji Sato, Carita Lanner, Kristine Breeden, Shao Ling Jing, Patrick B. Allen, Paul Greengard, Atsuko Yatani, Brian D. Hoit, Ingrid L. Grupp, Roger J. Hajjar, Anna A. DePaoli-Roach, Evangelia G. Kranias

Research output: Contribution to journalArticlepeer-review

217 Scopus citations


Increases in type 1 phosphatase (PP1) activity have been observed in end stage human heart failure, but the role of this enzyme in cardiac function is unknown. To elucidate the functional significance of increased PP1 activity, we generated models with (i) overexpression of the catalytic subunit of PP1 in murine hearts and (ii) ablation of the PP1-specific inhibitor. Overexpression of PP1 (threefold) was associated with depressed cardiac function, dilated cardiomyopathy, and premature mortality, consistent with heart failure. Ablation of the inhibitor was associated with moderate increases in PP1 activity (23%) and impaired β-adrenergic contractile responses. Extension of these findings to human heart failure indicated that the increased PP1 activity may be partially due to dephosphorylation or inactivation of its inhibitor. Indeed, expression of a constitutively active inhibitor was associated with rescue of β-adrenergic responsiveness in failing human myocytes. Thus, PP1 is an important regulator of cardiac function, and inhibition of its activity may represent a novel therapeutic target in heart failure.

Original languageEnglish
Pages (from-to)4124-4135
Number of pages12
JournalMolecular and Cellular Biology
Issue number12
StatePublished - 2002
Externally publishedYes


Dive into the research topics of 'Type 1 phosphatase, a negative regulator of cardiac function'. Together they form a unique fingerprint.

Cite this